User login
Trends in teen consumption of sports drinks are up and down
Although daily consumption of sports drinks decreased from 2010 to 2015 among teenagers, sugar-sweetened sports drinks still are popular, with numerous high school students drinking them at least weekly, said Kyla Cordery of the Steven and Alexandra Cohen Children’s Medical Center of New York, Lake Success, N.Y., and her associates.
Yet sports drink consumption in the previous week increased from 58% in 2010 to 60% in 2015 (P = .0002). And daily consumption of sports drinks also increased among teenagers watching television for more than 2 hours per day and among obese teens.
Boys were more than twice as likely as girls to drink one of more sports drinks daily (19% vs. 9%), as were more athletic/active children than those weren’t very athletic/active (18% vs. 10%).
“ Like many sugar-sweetened beverages, the excessive consumption of sports drinks is associated with weight gain, dental erosion, obesity, poor nutrition, and diabetes,” Ms. Cordery and her associates wrote. “The America Academy of Pediatrics’ Committee on Nutrition and Council on Sports Medicine and Fitness stated that the level of physical activity of the average child does not require the electrolyte replenishment offered by sports drinks.” Rehydration with water should be encouraged for most sports-related activities.
SOURCE: Cordery K et al. doi: 10.1542/peds.2017-2784.
Although daily consumption of sports drinks decreased from 2010 to 2015 among teenagers, sugar-sweetened sports drinks still are popular, with numerous high school students drinking them at least weekly, said Kyla Cordery of the Steven and Alexandra Cohen Children’s Medical Center of New York, Lake Success, N.Y., and her associates.
Yet sports drink consumption in the previous week increased from 58% in 2010 to 60% in 2015 (P = .0002). And daily consumption of sports drinks also increased among teenagers watching television for more than 2 hours per day and among obese teens.
Boys were more than twice as likely as girls to drink one of more sports drinks daily (19% vs. 9%), as were more athletic/active children than those weren’t very athletic/active (18% vs. 10%).
“ Like many sugar-sweetened beverages, the excessive consumption of sports drinks is associated with weight gain, dental erosion, obesity, poor nutrition, and diabetes,” Ms. Cordery and her associates wrote. “The America Academy of Pediatrics’ Committee on Nutrition and Council on Sports Medicine and Fitness stated that the level of physical activity of the average child does not require the electrolyte replenishment offered by sports drinks.” Rehydration with water should be encouraged for most sports-related activities.
SOURCE: Cordery K et al. doi: 10.1542/peds.2017-2784.
Although daily consumption of sports drinks decreased from 2010 to 2015 among teenagers, sugar-sweetened sports drinks still are popular, with numerous high school students drinking them at least weekly, said Kyla Cordery of the Steven and Alexandra Cohen Children’s Medical Center of New York, Lake Success, N.Y., and her associates.
Yet sports drink consumption in the previous week increased from 58% in 2010 to 60% in 2015 (P = .0002). And daily consumption of sports drinks also increased among teenagers watching television for more than 2 hours per day and among obese teens.
Boys were more than twice as likely as girls to drink one of more sports drinks daily (19% vs. 9%), as were more athletic/active children than those weren’t very athletic/active (18% vs. 10%).
“ Like many sugar-sweetened beverages, the excessive consumption of sports drinks is associated with weight gain, dental erosion, obesity, poor nutrition, and diabetes,” Ms. Cordery and her associates wrote. “The America Academy of Pediatrics’ Committee on Nutrition and Council on Sports Medicine and Fitness stated that the level of physical activity of the average child does not require the electrolyte replenishment offered by sports drinks.” Rehydration with water should be encouraged for most sports-related activities.
SOURCE: Cordery K et al. doi: 10.1542/peds.2017-2784.
FROM PEDIATRICS
SCVD common in women with type 1 diabetes
BOSTON – Women with type 1 diabetes had a high prevalence of systemic collagen vascular diseases in a recent study, suggesting a global or progressive loss of immune tolerance, investigators reported at the annual meeting of the American Association of Clinical Endocrinologists.
“The median time of diagnosis for most of those autoimmune diseases was years after the diabetes diagnosis,” according to investigator Yicheng Bao, a medical student at University of Missouri-Kansas City.*
“I think there’s some loss of immune tolerance in these patients with type 1 diabetes that really deserves more study as these patients get older,” Mr. Bao said in a video interview.
The study from Mr. Bao and his colleagues was based on patient questionnaire responses and medical chart reviews for 1,167 adults with type 1 diabetes, including 628 women.
They found that SCVDs occurred in 9.2% of women, who had a significantly higher risk versus men (adjusted odds ratio, 2.57; 95% confidence interval, 1.98-3.34; P less than 0.0001).
Rheumatoid arthritis was the most commonly diagnosed SCVD, occurring in 4.3% of the women, followed by psoriasis at 2.6% and lupus at 1.8%. Others occurring in less than 1% of women included Sjögren’s, mixed connective tissue disease, granulomatosis with polyangiitis, juvenile RA, and scleroderma.
Older women were at higher risk of SCVD, with a mean age of 53.6 years versus 46.3 years for women with no SCVD (P = 0.006).
Looking at both men and women, investigators found that individuals with type 1 diabetes and an SCVD were more likely to have other autoimmune diseases, such as hypothyroidism, hyperthyroidism, and celiac disease (adjusted OR, 2.8; 95% CI, 1.71-4.60; P less than 0.0001).
Based on these findings, clinicians taking care of adults with type 1 diabetes need to be vigilant about checking for collagen vascular autoimmune diseases on review of systems, particularly in older women, Mr. Bao said.
“If the patient has a collagen vascular autoimmune disease with type 1 diabetes, they really need to be checking for these other autoimmune diseases,” he added.
Mr. Bao had no disclosures to report.
*This article was updated on May 18, 2018.
BOSTON – Women with type 1 diabetes had a high prevalence of systemic collagen vascular diseases in a recent study, suggesting a global or progressive loss of immune tolerance, investigators reported at the annual meeting of the American Association of Clinical Endocrinologists.
“The median time of diagnosis for most of those autoimmune diseases was years after the diabetes diagnosis,” according to investigator Yicheng Bao, a medical student at University of Missouri-Kansas City.*
“I think there’s some loss of immune tolerance in these patients with type 1 diabetes that really deserves more study as these patients get older,” Mr. Bao said in a video interview.
The study from Mr. Bao and his colleagues was based on patient questionnaire responses and medical chart reviews for 1,167 adults with type 1 diabetes, including 628 women.
They found that SCVDs occurred in 9.2% of women, who had a significantly higher risk versus men (adjusted odds ratio, 2.57; 95% confidence interval, 1.98-3.34; P less than 0.0001).
Rheumatoid arthritis was the most commonly diagnosed SCVD, occurring in 4.3% of the women, followed by psoriasis at 2.6% and lupus at 1.8%. Others occurring in less than 1% of women included Sjögren’s, mixed connective tissue disease, granulomatosis with polyangiitis, juvenile RA, and scleroderma.
Older women were at higher risk of SCVD, with a mean age of 53.6 years versus 46.3 years for women with no SCVD (P = 0.006).
Looking at both men and women, investigators found that individuals with type 1 diabetes and an SCVD were more likely to have other autoimmune diseases, such as hypothyroidism, hyperthyroidism, and celiac disease (adjusted OR, 2.8; 95% CI, 1.71-4.60; P less than 0.0001).
Based on these findings, clinicians taking care of adults with type 1 diabetes need to be vigilant about checking for collagen vascular autoimmune diseases on review of systems, particularly in older women, Mr. Bao said.
“If the patient has a collagen vascular autoimmune disease with type 1 diabetes, they really need to be checking for these other autoimmune diseases,” he added.
Mr. Bao had no disclosures to report.
*This article was updated on May 18, 2018.
BOSTON – Women with type 1 diabetes had a high prevalence of systemic collagen vascular diseases in a recent study, suggesting a global or progressive loss of immune tolerance, investigators reported at the annual meeting of the American Association of Clinical Endocrinologists.
“The median time of diagnosis for most of those autoimmune diseases was years after the diabetes diagnosis,” according to investigator Yicheng Bao, a medical student at University of Missouri-Kansas City.*
“I think there’s some loss of immune tolerance in these patients with type 1 diabetes that really deserves more study as these patients get older,” Mr. Bao said in a video interview.
The study from Mr. Bao and his colleagues was based on patient questionnaire responses and medical chart reviews for 1,167 adults with type 1 diabetes, including 628 women.
They found that SCVDs occurred in 9.2% of women, who had a significantly higher risk versus men (adjusted odds ratio, 2.57; 95% confidence interval, 1.98-3.34; P less than 0.0001).
Rheumatoid arthritis was the most commonly diagnosed SCVD, occurring in 4.3% of the women, followed by psoriasis at 2.6% and lupus at 1.8%. Others occurring in less than 1% of women included Sjögren’s, mixed connective tissue disease, granulomatosis with polyangiitis, juvenile RA, and scleroderma.
Older women were at higher risk of SCVD, with a mean age of 53.6 years versus 46.3 years for women with no SCVD (P = 0.006).
Looking at both men and women, investigators found that individuals with type 1 diabetes and an SCVD were more likely to have other autoimmune diseases, such as hypothyroidism, hyperthyroidism, and celiac disease (adjusted OR, 2.8; 95% CI, 1.71-4.60; P less than 0.0001).
Based on these findings, clinicians taking care of adults with type 1 diabetes need to be vigilant about checking for collagen vascular autoimmune diseases on review of systems, particularly in older women, Mr. Bao said.
“If the patient has a collagen vascular autoimmune disease with type 1 diabetes, they really need to be checking for these other autoimmune diseases,” he added.
Mr. Bao had no disclosures to report.
*This article was updated on May 18, 2018.
REPORTING FROM AACE 2018
Key clinical point: The high incidence of systemic collagen vascular diseases in women with type 1 diabetes suggests a potential progressive loss of immune tolerance.
Major finding: Systemic collagen vascular diseases occurred in 9.2% of women, who had a significantly higher risk versus men (adjusted odds ratio, 2.57; 95% confidence interval, 1.98-3.34; P less than 0.0001).
Study details: A nonrandomized study including retrospective chart review and responses to questionnaires for 1,212 individuals with type 1 diabetes.
Disclosures: Mr. Bao had no disclosures to report.
VIDEO: First year after bariatric surgery critical for HbA1c improvement
BOSTON – Acute weight loss during the first year after bariatric surgery has a significant effect on hemoglobin A1c level improvement at 5 years’ follow-up, according to a study presented at the annual meeting of the American Association of Clinical Endocrinologists.
The data presented could help clinicians understand when and where to focus their efforts to help patients optimize weight loss in order to see the best long-term benefits of the procedure, according to presenter Keren Zhou, MD, an endocrinology fellow at the Cleveland Clinic.
“Clinicians need to really focus on that first year weight loss after bariatric surgery to try and optimize 5-year A1c outcomes,” said Dr. Zhou. “It also answers another question people have been having, which is how much does weight regain after bariatric surgery really matter? What we’ve been able to show here is that weight regain didn’t look very correlated at all.”
Dr. Zhou and her colleagues developed the ancillary study using data from the STAMPEDE (Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently) trial, specifically looking at 96 patients: 49 who underwent bariatric surgery and 47 who had a sleeve gastrectomy.
Patients were majority female, on average 48 years old, with a mean body mass index of 36.5 and HbA1c level of 9.4.
Overall, bariatric surgery patients lost an average of 27.2% in the first year, and regained around 8.2% from the first to fifth year, while sleeve gastrectomy lost and regained 25.1% and 9.4% respectively.
When comparing weight loss in the first year and HbA1c levels, Dr. Zhou and her colleagues found a significant correlation for both bariatric surgery and sleeve gastrectomy patients (r +.34; P = .0006).
“It was interesting because when we graphically represented the weight changes in addition to the A1c over time, we found that they actually correlated quite closely, but it was only when we did the statistical analysis on the numbers that we found that [in both groups] people who lost less weight had a higher A1c at the 5-year mark,” said Dr. Zhou.
In the non–multivariable analysis, however, investigators found a more significant correlation between weight regain and HbA1c levels in gastrectomy patients, however these findings changed when Dr. Zhou and her fellow investigators controlled for insulin use and baseline C-peptide.
In continuing studies, Dr. Zhou and her team will dive deeper into why these correlations exist, as right now they can only speculate.
Dr. Zhou reported no relevant financial disclosures.
SOURCE: Zhou K et al. AACE 18. Abstract 240-F.
BOSTON – Acute weight loss during the first year after bariatric surgery has a significant effect on hemoglobin A1c level improvement at 5 years’ follow-up, according to a study presented at the annual meeting of the American Association of Clinical Endocrinologists.
The data presented could help clinicians understand when and where to focus their efforts to help patients optimize weight loss in order to see the best long-term benefits of the procedure, according to presenter Keren Zhou, MD, an endocrinology fellow at the Cleveland Clinic.
“Clinicians need to really focus on that first year weight loss after bariatric surgery to try and optimize 5-year A1c outcomes,” said Dr. Zhou. “It also answers another question people have been having, which is how much does weight regain after bariatric surgery really matter? What we’ve been able to show here is that weight regain didn’t look very correlated at all.”
Dr. Zhou and her colleagues developed the ancillary study using data from the STAMPEDE (Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently) trial, specifically looking at 96 patients: 49 who underwent bariatric surgery and 47 who had a sleeve gastrectomy.
Patients were majority female, on average 48 years old, with a mean body mass index of 36.5 and HbA1c level of 9.4.
Overall, bariatric surgery patients lost an average of 27.2% in the first year, and regained around 8.2% from the first to fifth year, while sleeve gastrectomy lost and regained 25.1% and 9.4% respectively.
When comparing weight loss in the first year and HbA1c levels, Dr. Zhou and her colleagues found a significant correlation for both bariatric surgery and sleeve gastrectomy patients (r +.34; P = .0006).
“It was interesting because when we graphically represented the weight changes in addition to the A1c over time, we found that they actually correlated quite closely, but it was only when we did the statistical analysis on the numbers that we found that [in both groups] people who lost less weight had a higher A1c at the 5-year mark,” said Dr. Zhou.
In the non–multivariable analysis, however, investigators found a more significant correlation between weight regain and HbA1c levels in gastrectomy patients, however these findings changed when Dr. Zhou and her fellow investigators controlled for insulin use and baseline C-peptide.
In continuing studies, Dr. Zhou and her team will dive deeper into why these correlations exist, as right now they can only speculate.
Dr. Zhou reported no relevant financial disclosures.
SOURCE: Zhou K et al. AACE 18. Abstract 240-F.
BOSTON – Acute weight loss during the first year after bariatric surgery has a significant effect on hemoglobin A1c level improvement at 5 years’ follow-up, according to a study presented at the annual meeting of the American Association of Clinical Endocrinologists.
The data presented could help clinicians understand when and where to focus their efforts to help patients optimize weight loss in order to see the best long-term benefits of the procedure, according to presenter Keren Zhou, MD, an endocrinology fellow at the Cleveland Clinic.
“Clinicians need to really focus on that first year weight loss after bariatric surgery to try and optimize 5-year A1c outcomes,” said Dr. Zhou. “It also answers another question people have been having, which is how much does weight regain after bariatric surgery really matter? What we’ve been able to show here is that weight regain didn’t look very correlated at all.”
Dr. Zhou and her colleagues developed the ancillary study using data from the STAMPEDE (Surgical Treatment and Medications Potentially Eradicate Diabetes Efficiently) trial, specifically looking at 96 patients: 49 who underwent bariatric surgery and 47 who had a sleeve gastrectomy.
Patients were majority female, on average 48 years old, with a mean body mass index of 36.5 and HbA1c level of 9.4.
Overall, bariatric surgery patients lost an average of 27.2% in the first year, and regained around 8.2% from the first to fifth year, while sleeve gastrectomy lost and regained 25.1% and 9.4% respectively.
When comparing weight loss in the first year and HbA1c levels, Dr. Zhou and her colleagues found a significant correlation for both bariatric surgery and sleeve gastrectomy patients (r +.34; P = .0006).
“It was interesting because when we graphically represented the weight changes in addition to the A1c over time, we found that they actually correlated quite closely, but it was only when we did the statistical analysis on the numbers that we found that [in both groups] people who lost less weight had a higher A1c at the 5-year mark,” said Dr. Zhou.
In the non–multivariable analysis, however, investigators found a more significant correlation between weight regain and HbA1c levels in gastrectomy patients, however these findings changed when Dr. Zhou and her fellow investigators controlled for insulin use and baseline C-peptide.
In continuing studies, Dr. Zhou and her team will dive deeper into why these correlations exist, as right now they can only speculate.
Dr. Zhou reported no relevant financial disclosures.
SOURCE: Zhou K et al. AACE 18. Abstract 240-F.
REPORTING FROM AACE 18
Key clinical point:
Major finding: Change in weight within the first year was significantly correlated with lower HbA1c levels at 5 years (P = .0003).
Study details: Ancillary study of 96 patients who underwent either bariatric surgery or sleeve gastrectomy and participated in the STAMPEDE study.
Disclosures: Presenter reported no relevant financial disclosures.
Source: Zhou K et al. AACE 18. Abstract 240-F.
Diabetes spending topped $101 billion in 2013
according to investigators from the University of Washington, Seattle.
The largest share of personal health spending on diabetes in 2013 went for prescribed retail pharmaceuticals, which tallied over $58 billion. That was followed by ambulatory care at $24 billion, inpatient care at just under $10 billion, nursing home care at $9 billion, and emergency department care at $0.4 billion, Ellen Squires and her associates said in Diabetes Care.
“The rate of increase in pharmaceutical spending was especially drastic from 2008 to 2013, and research suggests that these upward trends have continued in more recent years,” Ms. Squires and her associates wrote.
The analysis used data from the Institute for Health Metrics and Evaluation’s Disease Expenditure 2013 database and the Global Burden of Disease 2016 study. The current study was funded by the Peterson Center on Healthcare and the National Institute on Aging. One investigator receives research support from Medtronic Diabetes and is a consultant for Abbott Diabetes Care, Bigfoot Biomedical, Adocia, and Roche. No other relevant conflicts of interest were reported.
SOURCE: Squires E et al. Diabetes Care. 2018 May 10. doi: 10.2337/dc17-1376.
according to investigators from the University of Washington, Seattle.
The largest share of personal health spending on diabetes in 2013 went for prescribed retail pharmaceuticals, which tallied over $58 billion. That was followed by ambulatory care at $24 billion, inpatient care at just under $10 billion, nursing home care at $9 billion, and emergency department care at $0.4 billion, Ellen Squires and her associates said in Diabetes Care.
“The rate of increase in pharmaceutical spending was especially drastic from 2008 to 2013, and research suggests that these upward trends have continued in more recent years,” Ms. Squires and her associates wrote.
The analysis used data from the Institute for Health Metrics and Evaluation’s Disease Expenditure 2013 database and the Global Burden of Disease 2016 study. The current study was funded by the Peterson Center on Healthcare and the National Institute on Aging. One investigator receives research support from Medtronic Diabetes and is a consultant for Abbott Diabetes Care, Bigfoot Biomedical, Adocia, and Roche. No other relevant conflicts of interest were reported.
SOURCE: Squires E et al. Diabetes Care. 2018 May 10. doi: 10.2337/dc17-1376.
according to investigators from the University of Washington, Seattle.
The largest share of personal health spending on diabetes in 2013 went for prescribed retail pharmaceuticals, which tallied over $58 billion. That was followed by ambulatory care at $24 billion, inpatient care at just under $10 billion, nursing home care at $9 billion, and emergency department care at $0.4 billion, Ellen Squires and her associates said in Diabetes Care.
“The rate of increase in pharmaceutical spending was especially drastic from 2008 to 2013, and research suggests that these upward trends have continued in more recent years,” Ms. Squires and her associates wrote.
The analysis used data from the Institute for Health Metrics and Evaluation’s Disease Expenditure 2013 database and the Global Burden of Disease 2016 study. The current study was funded by the Peterson Center on Healthcare and the National Institute on Aging. One investigator receives research support from Medtronic Diabetes and is a consultant for Abbott Diabetes Care, Bigfoot Biomedical, Adocia, and Roche. No other relevant conflicts of interest were reported.
SOURCE: Squires E et al. Diabetes Care. 2018 May 10. doi: 10.2337/dc17-1376.
FROM DIABETES CARE
Diabetic Ketoacidosis Takes a Turn for the Worse
Diabetic ketoacidosis (DKA) is life threatening, but preventable. It was good news that between 2000-2009, rates of DKA began to decline, but researchers from the Centers for Disease Control and Prevention (CDC) say it is “concerning” to find that those rates began to reverse between 2009-2014 , increasing 54.9%. All age groups saw an increase of ≥ 6% annually. The highest rates were among people aged < 45 years: approximately 27 times higher than among people aged > 65 years.
The causes for the reversal are not clear, the researchers say, but they offer several possibilities, including changes in case definition, new medications that might raise the risk of DKA, and higher admission rates for people with less serious disease.
Because DKA rates were highest among people aged > 45 years, the researchers say information from studies in that age group might help determine whether prevention strategies should focus on factors such as symptom recognition, adherence to treatment, self-management skills, access to care, or cost of treatment.
Diabetic ketoacidosis (DKA) is life threatening, but preventable. It was good news that between 2000-2009, rates of DKA began to decline, but researchers from the Centers for Disease Control and Prevention (CDC) say it is “concerning” to find that those rates began to reverse between 2009-2014 , increasing 54.9%. All age groups saw an increase of ≥ 6% annually. The highest rates were among people aged < 45 years: approximately 27 times higher than among people aged > 65 years.
The causes for the reversal are not clear, the researchers say, but they offer several possibilities, including changes in case definition, new medications that might raise the risk of DKA, and higher admission rates for people with less serious disease.
Because DKA rates were highest among people aged > 45 years, the researchers say information from studies in that age group might help determine whether prevention strategies should focus on factors such as symptom recognition, adherence to treatment, self-management skills, access to care, or cost of treatment.
Diabetic ketoacidosis (DKA) is life threatening, but preventable. It was good news that between 2000-2009, rates of DKA began to decline, but researchers from the Centers for Disease Control and Prevention (CDC) say it is “concerning” to find that those rates began to reverse between 2009-2014 , increasing 54.9%. All age groups saw an increase of ≥ 6% annually. The highest rates were among people aged < 45 years: approximately 27 times higher than among people aged > 65 years.
The causes for the reversal are not clear, the researchers say, but they offer several possibilities, including changes in case definition, new medications that might raise the risk of DKA, and higher admission rates for people with less serious disease.
Because DKA rates were highest among people aged > 45 years, the researchers say information from studies in that age group might help determine whether prevention strategies should focus on factors such as symptom recognition, adherence to treatment, self-management skills, access to care, or cost of treatment.
Boston and beyond: Stay connected at #AACE2018
Come on. Everyone knows the best part of any conference is meeting up with colleagues, mentors, and friends. So here’s how to do it at (or away from) the annual meeting of the American Association of Clinical Endocrinologists in Boston on May 16-20.
No one is immune from the pull of colleagues past, present, and even future, not even the program chair Vin Tangpricha, MD, who gave the lowdown in an interview on the best venues for getting in touch. 
- Thursday Night Chapter Receptions: After the first full day of the meeting, start in the room for your home chapter, then jump to your home state’s chapter, then your training chapter, and so on. This is the easiest and most exciting way at the meeting to connect with your web of colleagues, Dr. Tangpricha suggested enthusiastically. And don’t forget about AACE members from across the globe in the International Chapter Reception, in the biggest (and most fun, by some reports) party room by far. The receptions for all 22 domestic chapters and international members representing 102 countries will be held in the Sheraton Boston Hotel at 6 p.m.
- Wine and Cheese Reception: A Friday night tradition at AACE, from 4:30 p.m. to 6:30 p.m. in the exhibit hall, this offers a needed break at the end of the second full day of sessions to chat with colleagues, see exhibits, and check out posters.
- Women’s Luncheon: Thursday from 12 p.m. to 2:00 p.m. on Level C. In its fifth year, this luncheon has practically outgrown the meeting, with women entering endocrinology outpacing men. Good luck getting tickets; it’s always popular, Dr. Tangpricha said.
SeanPavonePhot/Thinkstock - College Breakfast With the Masters: This first-time-ever event welcomes and celebrates all past Masters of the American College of Endocrinology (MACEs). In this free, ticketed event on Saturday morning from 6:30 a.m. to 8 a.m., the largest assembly of MACEs ever gathered in the same room will be introduced to newer AACE fellows, who will then have the opportunity to meet with Masters and gather their insights on how to further their own careers in endocrinology, Dr. Tangpricha said.
- President’s Gala: This ticketed event open to members and family is always a great finale to the meeting, held Saturday night after the convocation, is one Dr. Tangpricha always looks forward to. This family-friendly event features food, libations, and live music.
- Social networking: Stay in touch with attendees and endocrinologists following the events and news from the meeting at #AACE2018, and with a Boston Strong–inspired hashtag of #ClinicalEndoStrong.
Come on. Everyone knows the best part of any conference is meeting up with colleagues, mentors, and friends. So here’s how to do it at (or away from) the annual meeting of the American Association of Clinical Endocrinologists in Boston on May 16-20.
No one is immune from the pull of colleagues past, present, and even future, not even the program chair Vin Tangpricha, MD, who gave the lowdown in an interview on the best venues for getting in touch.
- Thursday Night Chapter Receptions: After the first full day of the meeting, start in the room for your home chapter, then jump to your home state’s chapter, then your training chapter, and so on. This is the easiest and most exciting way at the meeting to connect with your web of colleagues, Dr. Tangpricha suggested enthusiastically. And don’t forget about AACE members from across the globe in the International Chapter Reception, in the biggest (and most fun, by some reports) party room by far. The receptions for all 22 domestic chapters and international members representing 102 countries will be held in the Sheraton Boston Hotel at 6 p.m.
- Wine and Cheese Reception: A Friday night tradition at AACE, from 4:30 p.m. to 6:30 p.m. in the exhibit hall, this offers a needed break at the end of the second full day of sessions to chat with colleagues, see exhibits, and check out posters.
- Women’s Luncheon: Thursday from 12 p.m. to 2:00 p.m. on Level C. In its fifth year, this luncheon has practically outgrown the meeting, with women entering endocrinology outpacing men. Good luck getting tickets; it’s always popular, Dr. Tangpricha said.
SeanPavonePhot/Thinkstock
- College Breakfast With the Masters: This first-time-ever event welcomes and celebrates all past Masters of the American College of Endocrinology (MACEs). In this free, ticketed event on Saturday morning from 6:30 a.m. to 8 a.m., the largest assembly of MACEs ever gathered in the same room will be introduced to newer AACE fellows, who will then have the opportunity to meet with Masters and gather their insights on how to further their own careers in endocrinology, Dr. Tangpricha said.
- President’s Gala: This ticketed event open to members and family is always a great finale to the meeting, held Saturday night after the convocation, is one Dr. Tangpricha always looks forward to. This family-friendly event features food, libations, and live music.
- Social networking: Stay in touch with attendees and endocrinologists following the events and news from the meeting at #AACE2018, and with a Boston Strong–inspired hashtag of #ClinicalEndoStrong.
Come on. Everyone knows the best part of any conference is meeting up with colleagues, mentors, and friends. So here’s how to do it at (or away from) the annual meeting of the American Association of Clinical Endocrinologists in Boston on May 16-20.
No one is immune from the pull of colleagues past, present, and even future, not even the program chair Vin Tangpricha, MD, who gave the lowdown in an interview on the best venues for getting in touch.
- Thursday Night Chapter Receptions: After the first full day of the meeting, start in the room for your home chapter, then jump to your home state’s chapter, then your training chapter, and so on. This is the easiest and most exciting way at the meeting to connect with your web of colleagues, Dr. Tangpricha suggested enthusiastically. And don’t forget about AACE members from across the globe in the International Chapter Reception, in the biggest (and most fun, by some reports) party room by far. The receptions for all 22 domestic chapters and international members representing 102 countries will be held in the Sheraton Boston Hotel at 6 p.m.
- Wine and Cheese Reception: A Friday night tradition at AACE, from 4:30 p.m. to 6:30 p.m. in the exhibit hall, this offers a needed break at the end of the second full day of sessions to chat with colleagues, see exhibits, and check out posters.
- Women’s Luncheon: Thursday from 12 p.m. to 2:00 p.m. on Level C. In its fifth year, this luncheon has practically outgrown the meeting, with women entering endocrinology outpacing men. Good luck getting tickets; it’s always popular, Dr. Tangpricha said.
SeanPavonePhot/Thinkstock
- College Breakfast With the Masters: This first-time-ever event welcomes and celebrates all past Masters of the American College of Endocrinology (MACEs). In this free, ticketed event on Saturday morning from 6:30 a.m. to 8 a.m., the largest assembly of MACEs ever gathered in the same room will be introduced to newer AACE fellows, who will then have the opportunity to meet with Masters and gather their insights on how to further their own careers in endocrinology, Dr. Tangpricha said.
- President’s Gala: This ticketed event open to members and family is always a great finale to the meeting, held Saturday night after the convocation, is one Dr. Tangpricha always looks forward to. This family-friendly event features food, libations, and live music.
- Social networking: Stay in touch with attendees and endocrinologists following the events and news from the meeting at #AACE2018, and with a Boston Strong–inspired hashtag of #ClinicalEndoStrong.
FROM AACE 2018
AACE 2018: A dream team of presenters
Boston is the location and inspiration for the featured presentations at the annual meeting of the American Association of Clinical Endocrinologists, program chair Vin Tangpricha, MD, PhD, said in an interview.
The program agenda for the congress, held May 16-20, boasts 143 speakers, 66 distinct clinical endocrinology educational sessions, and an opening plenary presentation featuring one of modern medicine’s most renowned diabetes and obesity researchers, according to a statement from the AACE.
New Dimensions in Insulin Action and Why They Are Important to Know
C. Ronald Kahn, MD, chief academic officer and head of Integrative Physiology and Metabolism at Joslin Diabetes Center in Boston, pioneered revolutionary work with insulin receptors and insulin resistance in diabetes and obesity. What makes his presentation on Thursday from 8:30 a.m. to 9:15 a.m. a must-see is its focus on the future: “Many new drugs are being developed based on the research on how insulin works. This lecture will be exciting to hear what is in the pipeline for drugs that manipulate insulin action,” Dr. Tangpricha said.
Cushing’s Syndrome
Beta-Cell Regeneration
The work of Andrew F. Stewart, MD, scientific director of the Mount Sinai Diabetes, Obesity and Metabolism Institute in New York, leads research into the basic mechanisms, prevention, and treatment of metabolic diseases. “In the past, we thought that there was a fixed number of beta cells in the body. However, recent research by Dr. Stewart’s group suggests that beta cells can be stimulated to grow. This is very exciting and can shape the future of how we take care of diabetes,” noted Dr. Tangpricha. The session is on Friday from 8:20 a.m. to 9:05 a.m.
New Insights Into Thyroid Hormone Action
On Thursday from 11:15 a.m. to 12:00 p.m., Anthony N. Hollenberg, MD, will present “an outstanding review on thyroid hormone and action and how this impacts patient care of those with thyroid disease,” Dr. Tangpricha said. Dr. Hollenberg is chief of the thyroid unit and the division of endocrinology, diabetes, and metabolism at Beth Israel Deaconess Medical Center in Boston.
Current and Evolving Approaches for Osteoporosis Treatment
Sundeep Khosla, MD, an expert on bone loss, will distill the myriad osteoporosis treatments into useful information that can inform your practice now. “There have been a number of drugs that have been released for the treatment of osteoporosis. We are now in an era where we can consider using drugs targeted for specific populations or specific combinations,” Dr. Tangpricha commented. This session is on Saturday at 8:15 a.m. to 9:00 a.m.
Boston is the location and inspiration for the featured presentations at the annual meeting of the American Association of Clinical Endocrinologists, program chair Vin Tangpricha, MD, PhD, said in an interview.
The program agenda for the congress, held May 16-20, boasts 143 speakers, 66 distinct clinical endocrinology educational sessions, and an opening plenary presentation featuring one of modern medicine’s most renowned diabetes and obesity researchers, according to a statement from the AACE.
New Dimensions in Insulin Action and Why They Are Important to Know
C. Ronald Kahn, MD, chief academic officer and head of Integrative Physiology and Metabolism at Joslin Diabetes Center in Boston, pioneered revolutionary work with insulin receptors and insulin resistance in diabetes and obesity. What makes his presentation on Thursday from 8:30 a.m. to 9:15 a.m. a must-see is its focus on the future: “Many new drugs are being developed based on the research on how insulin works. This lecture will be exciting to hear what is in the pipeline for drugs that manipulate insulin action,” Dr. Tangpricha said.
Cushing’s Syndrome
Beta-Cell Regeneration
The work of Andrew F. Stewart, MD, scientific director of the Mount Sinai Diabetes, Obesity and Metabolism Institute in New York, leads research into the basic mechanisms, prevention, and treatment of metabolic diseases. “In the past, we thought that there was a fixed number of beta cells in the body. However, recent research by Dr. Stewart’s group suggests that beta cells can be stimulated to grow. This is very exciting and can shape the future of how we take care of diabetes,” noted Dr. Tangpricha. The session is on Friday from 8:20 a.m. to 9:05 a.m.
New Insights Into Thyroid Hormone Action
On Thursday from 11:15 a.m. to 12:00 p.m., Anthony N. Hollenberg, MD, will present “an outstanding review on thyroid hormone and action and how this impacts patient care of those with thyroid disease,” Dr. Tangpricha said. Dr. Hollenberg is chief of the thyroid unit and the division of endocrinology, diabetes, and metabolism at Beth Israel Deaconess Medical Center in Boston.
Current and Evolving Approaches for Osteoporosis Treatment
Sundeep Khosla, MD, an expert on bone loss, will distill the myriad osteoporosis treatments into useful information that can inform your practice now. “There have been a number of drugs that have been released for the treatment of osteoporosis. We are now in an era where we can consider using drugs targeted for specific populations or specific combinations,” Dr. Tangpricha commented. This session is on Saturday at 8:15 a.m. to 9:00 a.m.
Boston is the location and inspiration for the featured presentations at the annual meeting of the American Association of Clinical Endocrinologists, program chair Vin Tangpricha, MD, PhD, said in an interview.
The program agenda for the congress, held May 16-20, boasts 143 speakers, 66 distinct clinical endocrinology educational sessions, and an opening plenary presentation featuring one of modern medicine’s most renowned diabetes and obesity researchers, according to a statement from the AACE.
New Dimensions in Insulin Action and Why They Are Important to Know
C. Ronald Kahn, MD, chief academic officer and head of Integrative Physiology and Metabolism at Joslin Diabetes Center in Boston, pioneered revolutionary work with insulin receptors and insulin resistance in diabetes and obesity. What makes his presentation on Thursday from 8:30 a.m. to 9:15 a.m. a must-see is its focus on the future: “Many new drugs are being developed based on the research on how insulin works. This lecture will be exciting to hear what is in the pipeline for drugs that manipulate insulin action,” Dr. Tangpricha said.
Cushing’s Syndrome
Beta-Cell Regeneration
The work of Andrew F. Stewart, MD, scientific director of the Mount Sinai Diabetes, Obesity and Metabolism Institute in New York, leads research into the basic mechanisms, prevention, and treatment of metabolic diseases. “In the past, we thought that there was a fixed number of beta cells in the body. However, recent research by Dr. Stewart’s group suggests that beta cells can be stimulated to grow. This is very exciting and can shape the future of how we take care of diabetes,” noted Dr. Tangpricha. The session is on Friday from 8:20 a.m. to 9:05 a.m.
New Insights Into Thyroid Hormone Action
On Thursday from 11:15 a.m. to 12:00 p.m., Anthony N. Hollenberg, MD, will present “an outstanding review on thyroid hormone and action and how this impacts patient care of those with thyroid disease,” Dr. Tangpricha said. Dr. Hollenberg is chief of the thyroid unit and the division of endocrinology, diabetes, and metabolism at Beth Israel Deaconess Medical Center in Boston.
Current and Evolving Approaches for Osteoporosis Treatment
Sundeep Khosla, MD, an expert on bone loss, will distill the myriad osteoporosis treatments into useful information that can inform your practice now. “There have been a number of drugs that have been released for the treatment of osteoporosis. We are now in an era where we can consider using drugs targeted for specific populations or specific combinations,” Dr. Tangpricha commented. This session is on Saturday at 8:15 a.m. to 9:00 a.m.
FROM AACE 2018
Original research expands at AACE 2018
This year’s meeting, in Boston May 16-20, has brought in a record number of accepted abstracts – 1,126 – in all areas of endocrinology. The lion’s share focuses on diabetes, thyroid disease, and bone disease. Most will be presented in Poster Viewing and Judging sessions at 10:00 a.m on Thursday for young investigators and during a poster viewing and wine and cheese reception from 4:30 p.m. to 6:30 p.m. on Friday for senior investigators.
Of note, the mother lode of clinical trials, retrospective analyses, and registry studies will be shown at the senior investigator competition on Friday evening.
That viewing session will include two post hoc analyses of data from the global SUSTAIN trial program in the investigational GLP-1 receptor agonist semaglutide. The first, Abstract 245, examines whether reductions in body weight and HbA1c differed between elderly and younger patients in SUSTAIN 7. The second, Abstract 298, is an analysis of SUSTAIN 1-5 and 7, looking at semaglutide’s effectiveness across racial and ethnic subgroups.
Another large trial, CANVAS, will be represented in two abstracts in this Friday session. In CANVAS, canagliflozin for primary prevention didn’t significantly reduce cardiovascular events in patients with at-risk type 2 diabetes, but it did so convincingly in a secondary prevention population. Outcomes by age group will be presented in Abstract 233, while those by changes in HbA1c and use of antihyperglycemic drugs will be presented in Abstract 262.
Other studies of interest in this viewing session include but are not limited to a comparison of the effects of hypnosis and certified diabetes educators on weight loss and changes in HbA1c levels (Abstract 602) and an investigation into whether the anabolic agent teriparatide can aid in foot bone remodeling in patients with Charcot neuroarthropathy (Abstract 225).
This year’s meeting, in Boston May 16-20, has brought in a record number of accepted abstracts – 1,126 – in all areas of endocrinology. The lion’s share focuses on diabetes, thyroid disease, and bone disease. Most will be presented in Poster Viewing and Judging sessions at 10:00 a.m on Thursday for young investigators and during a poster viewing and wine and cheese reception from 4:30 p.m. to 6:30 p.m. on Friday for senior investigators.
Of note, the mother lode of clinical trials, retrospective analyses, and registry studies will be shown at the senior investigator competition on Friday evening.
That viewing session will include two post hoc analyses of data from the global SUSTAIN trial program in the investigational GLP-1 receptor agonist semaglutide. The first, Abstract 245, examines whether reductions in body weight and HbA1c differed between elderly and younger patients in SUSTAIN 7. The second, Abstract 298, is an analysis of SUSTAIN 1-5 and 7, looking at semaglutide’s effectiveness across racial and ethnic subgroups.
Another large trial, CANVAS, will be represented in two abstracts in this Friday session. In CANVAS, canagliflozin for primary prevention didn’t significantly reduce cardiovascular events in patients with at-risk type 2 diabetes, but it did so convincingly in a secondary prevention population. Outcomes by age group will be presented in Abstract 233, while those by changes in HbA1c and use of antihyperglycemic drugs will be presented in Abstract 262.
Other studies of interest in this viewing session include but are not limited to a comparison of the effects of hypnosis and certified diabetes educators on weight loss and changes in HbA1c levels (Abstract 602) and an investigation into whether the anabolic agent teriparatide can aid in foot bone remodeling in patients with Charcot neuroarthropathy (Abstract 225).
This year’s meeting, in Boston May 16-20, has brought in a record number of accepted abstracts – 1,126 – in all areas of endocrinology. The lion’s share focuses on diabetes, thyroid disease, and bone disease. Most will be presented in Poster Viewing and Judging sessions at 10:00 a.m on Thursday for young investigators and during a poster viewing and wine and cheese reception from 4:30 p.m. to 6:30 p.m. on Friday for senior investigators.
Of note, the mother lode of clinical trials, retrospective analyses, and registry studies will be shown at the senior investigator competition on Friday evening.
That viewing session will include two post hoc analyses of data from the global SUSTAIN trial program in the investigational GLP-1 receptor agonist semaglutide. The first, Abstract 245, examines whether reductions in body weight and HbA1c differed between elderly and younger patients in SUSTAIN 7. The second, Abstract 298, is an analysis of SUSTAIN 1-5 and 7, looking at semaglutide’s effectiveness across racial and ethnic subgroups.
Another large trial, CANVAS, will be represented in two abstracts in this Friday session. In CANVAS, canagliflozin for primary prevention didn’t significantly reduce cardiovascular events in patients with at-risk type 2 diabetes, but it did so convincingly in a secondary prevention population. Outcomes by age group will be presented in Abstract 233, while those by changes in HbA1c and use of antihyperglycemic drugs will be presented in Abstract 262.
Other studies of interest in this viewing session include but are not limited to a comparison of the effects of hypnosis and certified diabetes educators on weight loss and changes in HbA1c levels (Abstract 602) and an investigation into whether the anabolic agent teriparatide can aid in foot bone remodeling in patients with Charcot neuroarthropathy (Abstract 225).
FROM AACE 2018
Parkinson’s disease patients have impaired insulin secretion
LOS ANGELES – Parkinson’s disease patients with long-standing disease should be screened for glucose dysregulation and treated with insulin releasing drugs, instead of insulin sensitizers, when necessary, according to a French investigation that compared 50 patients with 50 healthy controls matched for age, sex, and body mass index.
The subjects underwent a 75-g oral glucose tolerance test. Glucose levels were higher in the Parkinson’s disease (PD) group from about 60 minutes through the end of the test at 180 minutes; the differences were statistically significant at 90 and 150 minutes. The total blood glucose area under the time curve (AUC) was significantly higher in the PD group (1,187 vs. 1,101 mmol.min l-1; P = .05).
In short, “PD patients had higher blood glucose following oral glucose intake without … the expected concomitant rise in insulin levels, suggesting an under-active insulin response. PD patients with advanced disease” – all the patients had had PD for more than 5 years – “have impaired blood glucose levels in response to oral glucose intake,” said lead investigator Ana Marques, MD, of the Université Clermont Auvergne in Clermont-Ferrand, France.
“Blood glucose dysregulation should be screened in PD patients with moderate to advanced disease. Insulin releasing drugs should possibly be preferred [over] insulin sensitizer drugs in PD patients with diabetes,” she said at the annual meeting of the American Academy of Neurology.
Higher blood glucose levels were also associated with longer PD duration, lower dopaminergic therapy doses, and higher degrees of dysautonomia. Mean PD duration in the study was about 8 years, and mean levodopa-equivalent dose 884 mg/d.
The findings add weight to the proposed and still somewhat controversial link between PD and diabetes. “Dysglycemia appears to be another nonmotor consequence of PD,” Dr. Marques said. Because insulin production “is modulated by the autonomic nervous system, the severity of dysautonomia in PD could be linked with blood glucose dysregulation. Sympathetic denervation might lead to beta-cell dysfunction.”
Subjects were 61 years old, on average; two-thirds were men. The mean BMI was about 25 kg/m2. Patients were excluded if they had a change in dopaminergic therapy in the previous month, previous deep brain stimulation, medications that would interfere with glucose metabolism, or diabetes, among other things.
PD patients had slightly higher fasting urine glucose (P = .02). They also had lower fasting plasma insulin, but the difference wasn’t statistically significant (P = .5). Dysglycemia was also associated with higher BMI. Male gender and higher levodopa-equivalent doses were protective.
“The association between dysglycemia and PD is bilateral. In many studies, PD enhances the risk, but dysglycemia and particularly diabetes have been reported to increase the risk of PD. It goes both ways. There’s a lot that remains to be understood,” Dr. Marques said.
There was no external funding, and the investigators had nothing to disclose.
SOURCE: Marques A et al. Neurology. 2018 Apr 90(15 Suppl.):S3.008
LOS ANGELES – Parkinson’s disease patients with long-standing disease should be screened for glucose dysregulation and treated with insulin releasing drugs, instead of insulin sensitizers, when necessary, according to a French investigation that compared 50 patients with 50 healthy controls matched for age, sex, and body mass index.
The subjects underwent a 75-g oral glucose tolerance test. Glucose levels were higher in the Parkinson’s disease (PD) group from about 60 minutes through the end of the test at 180 minutes; the differences were statistically significant at 90 and 150 minutes. The total blood glucose area under the time curve (AUC) was significantly higher in the PD group (1,187 vs. 1,101 mmol.min l-1; P = .05).
In short, “PD patients had higher blood glucose following oral glucose intake without … the expected concomitant rise in insulin levels, suggesting an under-active insulin response. PD patients with advanced disease” – all the patients had had PD for more than 5 years – “have impaired blood glucose levels in response to oral glucose intake,” said lead investigator Ana Marques, MD, of the Université Clermont Auvergne in Clermont-Ferrand, France.
“Blood glucose dysregulation should be screened in PD patients with moderate to advanced disease. Insulin releasing drugs should possibly be preferred [over] insulin sensitizer drugs in PD patients with diabetes,” she said at the annual meeting of the American Academy of Neurology.
Higher blood glucose levels were also associated with longer PD duration, lower dopaminergic therapy doses, and higher degrees of dysautonomia. Mean PD duration in the study was about 8 years, and mean levodopa-equivalent dose 884 mg/d.
The findings add weight to the proposed and still somewhat controversial link between PD and diabetes. “Dysglycemia appears to be another nonmotor consequence of PD,” Dr. Marques said. Because insulin production “is modulated by the autonomic nervous system, the severity of dysautonomia in PD could be linked with blood glucose dysregulation. Sympathetic denervation might lead to beta-cell dysfunction.”
Subjects were 61 years old, on average; two-thirds were men. The mean BMI was about 25 kg/m2. Patients were excluded if they had a change in dopaminergic therapy in the previous month, previous deep brain stimulation, medications that would interfere with glucose metabolism, or diabetes, among other things.
PD patients had slightly higher fasting urine glucose (P = .02). They also had lower fasting plasma insulin, but the difference wasn’t statistically significant (P = .5). Dysglycemia was also associated with higher BMI. Male gender and higher levodopa-equivalent doses were protective.
“The association between dysglycemia and PD is bilateral. In many studies, PD enhances the risk, but dysglycemia and particularly diabetes have been reported to increase the risk of PD. It goes both ways. There’s a lot that remains to be understood,” Dr. Marques said.
There was no external funding, and the investigators had nothing to disclose.
SOURCE: Marques A et al. Neurology. 2018 Apr 90(15 Suppl.):S3.008
LOS ANGELES – Parkinson’s disease patients with long-standing disease should be screened for glucose dysregulation and treated with insulin releasing drugs, instead of insulin sensitizers, when necessary, according to a French investigation that compared 50 patients with 50 healthy controls matched for age, sex, and body mass index.
The subjects underwent a 75-g oral glucose tolerance test. Glucose levels were higher in the Parkinson’s disease (PD) group from about 60 minutes through the end of the test at 180 minutes; the differences were statistically significant at 90 and 150 minutes. The total blood glucose area under the time curve (AUC) was significantly higher in the PD group (1,187 vs. 1,101 mmol.min l-1; P = .05).
In short, “PD patients had higher blood glucose following oral glucose intake without … the expected concomitant rise in insulin levels, suggesting an under-active insulin response. PD patients with advanced disease” – all the patients had had PD for more than 5 years – “have impaired blood glucose levels in response to oral glucose intake,” said lead investigator Ana Marques, MD, of the Université Clermont Auvergne in Clermont-Ferrand, France.
“Blood glucose dysregulation should be screened in PD patients with moderate to advanced disease. Insulin releasing drugs should possibly be preferred [over] insulin sensitizer drugs in PD patients with diabetes,” she said at the annual meeting of the American Academy of Neurology.
Higher blood glucose levels were also associated with longer PD duration, lower dopaminergic therapy doses, and higher degrees of dysautonomia. Mean PD duration in the study was about 8 years, and mean levodopa-equivalent dose 884 mg/d.
The findings add weight to the proposed and still somewhat controversial link between PD and diabetes. “Dysglycemia appears to be another nonmotor consequence of PD,” Dr. Marques said. Because insulin production “is modulated by the autonomic nervous system, the severity of dysautonomia in PD could be linked with blood glucose dysregulation. Sympathetic denervation might lead to beta-cell dysfunction.”
Subjects were 61 years old, on average; two-thirds were men. The mean BMI was about 25 kg/m2. Patients were excluded if they had a change in dopaminergic therapy in the previous month, previous deep brain stimulation, medications that would interfere with glucose metabolism, or diabetes, among other things.
PD patients had slightly higher fasting urine glucose (P = .02). They also had lower fasting plasma insulin, but the difference wasn’t statistically significant (P = .5). Dysglycemia was also associated with higher BMI. Male gender and higher levodopa-equivalent doses were protective.
“The association between dysglycemia and PD is bilateral. In many studies, PD enhances the risk, but dysglycemia and particularly diabetes have been reported to increase the risk of PD. It goes both ways. There’s a lot that remains to be understood,” Dr. Marques said.
There was no external funding, and the investigators had nothing to disclose.
SOURCE: Marques A et al. Neurology. 2018 Apr 90(15 Suppl.):S3.008
REPORTING FROM AAN 2018
Key clinical point: instead of insulin sensitizers, when necessary.
Major finding: The total blood glucose area under the time curve was significantly higher in the PD group after oral glucose challenge.
Study details: A study of 50 PD patients and 50 controls.
Disclosures: There was no external funding, and the investigators had nothing to disclose.
Source: Marques A et al. Neurology. 2018 Apr 90(15 Suppl.):S3.008
Abstract: Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Poole, R., et al, BMJ 359:J5024, November 22, 2017
BACKGROUND: Studies examining the benefits versus harms of coffee consumption have yielded conflicting results.
METHODS: The authors, from the United Kingdom, present an umbrella review of meta-analyses published up to 2017 to determine the associations between coffee consumption and any health outcome in adults.
RESULTS: This review includes 201 meta-analyses of observational studies with 67 health outcomes and 17 meta-analyses of randomized trials with 9 health outcomes according to coffee consumption defined as high versus low, any versus none, or per each extra cup per day. Coffee was associated with statistically significant protective effects against several diseases including type 2 diabetes, renal stones, Parkinson’s disease, Alzheimer’s disease, depression, leukemia, gout, colorectal cancer, liver cancer, chronic liver disease, cirrhosis, and endometrial cancer (odds ratios of 0.35-0.94). For some outcomes including all-cause mortality, cardiovascular mortality and cardiovascular disease, a nonlinear association was found whereby 3-4 cups per day (versus 0) conferred the greatest risk reduction (by 17%, 19% and 15%, respectively). High versus low consumption reduced the risk of incident cancers by 18%. Significant harms included lung cancer, urinary tract cancer, pregnancy loss, low birth weight, preterm birth, acute leukemia in childhood, and fracture risk in women (odds ratios of 1.03-1.57). Many of the harms were mitigated after adjustment for smoking, except the risks during pregnancy. This analysis of observational trials cannot prove causality.
CONCLUSIONS: Moderate levels of coffee consumption appear to be safe or even beneficial, except during pregnancy and in women at high fracture risk. 132 references (r.poole@soton.ac.uk – no reprints)
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Poole, R., et al, BMJ 359:J5024, November 22, 2017
BACKGROUND: Studies examining the benefits versus harms of coffee consumption have yielded conflicting results.
METHODS: The authors, from the United Kingdom, present an umbrella review of meta-analyses published up to 2017 to determine the associations between coffee consumption and any health outcome in adults.
RESULTS: This review includes 201 meta-analyses of observational studies with 67 health outcomes and 17 meta-analyses of randomized trials with 9 health outcomes according to coffee consumption defined as high versus low, any versus none, or per each extra cup per day. Coffee was associated with statistically significant protective effects against several diseases including type 2 diabetes, renal stones, Parkinson’s disease, Alzheimer’s disease, depression, leukemia, gout, colorectal cancer, liver cancer, chronic liver disease, cirrhosis, and endometrial cancer (odds ratios of 0.35-0.94). For some outcomes including all-cause mortality, cardiovascular mortality and cardiovascular disease, a nonlinear association was found whereby 3-4 cups per day (versus 0) conferred the greatest risk reduction (by 17%, 19% and 15%, respectively). High versus low consumption reduced the risk of incident cancers by 18%. Significant harms included lung cancer, urinary tract cancer, pregnancy loss, low birth weight, preterm birth, acute leukemia in childhood, and fracture risk in women (odds ratios of 1.03-1.57). Many of the harms were mitigated after adjustment for smoking, except the risks during pregnancy. This analysis of observational trials cannot prove causality.
CONCLUSIONS: Moderate levels of coffee consumption appear to be safe or even beneficial, except during pregnancy and in women at high fracture risk. 132 references (r.poole@soton.ac.uk – no reprints)
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
Poole, R., et al, BMJ 359:J5024, November 22, 2017
BACKGROUND: Studies examining the benefits versus harms of coffee consumption have yielded conflicting results.
METHODS: The authors, from the United Kingdom, present an umbrella review of meta-analyses published up to 2017 to determine the associations between coffee consumption and any health outcome in adults.
RESULTS: This review includes 201 meta-analyses of observational studies with 67 health outcomes and 17 meta-analyses of randomized trials with 9 health outcomes according to coffee consumption defined as high versus low, any versus none, or per each extra cup per day. Coffee was associated with statistically significant protective effects against several diseases including type 2 diabetes, renal stones, Parkinson’s disease, Alzheimer’s disease, depression, leukemia, gout, colorectal cancer, liver cancer, chronic liver disease, cirrhosis, and endometrial cancer (odds ratios of 0.35-0.94). For some outcomes including all-cause mortality, cardiovascular mortality and cardiovascular disease, a nonlinear association was found whereby 3-4 cups per day (versus 0) conferred the greatest risk reduction (by 17%, 19% and 15%, respectively). High versus low consumption reduced the risk of incident cancers by 18%. Significant harms included lung cancer, urinary tract cancer, pregnancy loss, low birth weight, preterm birth, acute leukemia in childhood, and fracture risk in women (odds ratios of 1.03-1.57). Many of the harms were mitigated after adjustment for smoking, except the risks during pregnancy. This analysis of observational trials cannot prove causality.
CONCLUSIONS: Moderate levels of coffee consumption appear to be safe or even beneficial, except during pregnancy and in women at high fracture risk. 132 references (r.poole@soton.ac.uk – no reprints)
Learn more about the Primary Care Medical Abstracts and podcasts, for which you can earn up to 9 CME credits per month.
Copyright © The Center for Medical Education
